Sandeep Gupta

US Patent:

6687528, Feb 3, 2004

Filed:

Sep 28, 2001

Appl. No.:

09/967297

Inventors:

Sandeep N. Gupta - Baltimore MD
Garth M. Beache - Baltimore MD
Daniel A. Herzka - Silver Spring MD

Assignee:

GE Medical Systems Global Technology Company LLC - Waukesha WI
John Hopkins University - Baltimore MD

International Classification:

A61B 5055

US Classification:

600410, 382294, 382131, 382278

Abstract:

The present invention is a method and apparatus for semi-automatically registering low signal to noise ratio relaxation-time images, with particular application to tracking motion in moving organs and quantifying myocardial perfusion reserve. For each image acquired in a time series, a corresponding high signal to noise ratio image is extrapolated from the collected data. The high signal to noise ratio images are registered to track motion, and the resulting registration data is copied onto the corresponding relaxation time image.

US Patent:

7280862, Oct 9, 2007

Filed:

Aug 18, 2004

Appl. No.:

10/711025

Inventors:

Sandeep Narendra Gupta - Hanover MD, US
Glenn Scott Slavin - Silver Spring MD, US
Thomas Kwok-Fah Foo - Potomac MD, US

Assignee:

General Electric Company - Schenectady NY

International Classification:

A61B 5/05
A61B 5/02

US Classification:

600410, 600425, 600481, 600407

Abstract:

A system and a method for obtaining a digital image of a heart of a person are provided. The system scans an internal anatomy of a chest region of the person to obtain scanning data. The system further generates a digital image of four chambers of the heart based on the scanning data.

US Patent:

7620227, Nov 17, 2009

Filed:

Dec 29, 2005

Appl. No.:

11/321510

Inventors:

David Thomas Gering - Waukesha WI, US
Gopal B. Avinash - New Berlin WI, US
Sandeep N. Gupta - Hanover MD, US

Assignee:

General Electric Co. - Schenectady NY

International Classification:

G06K 9/00
A61B 5/05

US Classification:

382128, 382154, 600400

Abstract:

A computer-aided detection system for evaluating tissue based on a series of timed images acquired both before and after a contrast agent is administered performs a temporal analysis of the tissue and then a spatial analysis in which the tissue is categorized. After the temporal and spatial analysis is performed, the results can be displayed. The displayed results can include both tissue characterization results, underlying curves used to determine the characterization, and confidence data regarding how good the characterization is expected to be. The confidence data can be provided, for example, by using variations in color schemes, displaying numerical confidence levels, or providing graphical features such as piecewise linear models.

US Patent:

20050014743, Jan 20, 2005

Filed:

May 27, 2004

Appl. No.:

10/857597

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Gary Samoriski - Hillsborough NJ, US

Assignee:

Forest Laboratories, Inc. - New York NY

International Classification:

A61K031/551
A61K031/343

US Classification:

514220000, 514469000

Abstract:

The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.

US Patent:

20050113458, May 26, 2005

Filed:

Oct 22, 2004

Appl. No.:

10/971306

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Pradeep Banerjee - Hillsborough NJ, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US

Assignee:

Forest Laboratories, Inc. - New York NY

International Classification:

A61K031/13

US Classification:

514659000

Abstract:

The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aβ peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aβ peptides.

US Patent:

20060079582, Apr 13, 2006

Filed:

Sep 23, 2005

Appl. No.:

11/234764

Inventors:

Jeffrey Jonas - Hoboken NJ, US
Pradeep Banerjee - Hillsborough NJ, US
Sandeep Gupta - Plainsboro NJ, US
Allison Mann - Fort Lee NJ, US
Hans-Joerg Moebius - Frankfurt, DE

International Classification:

A61K 31/13

US Classification:

514662000

Abstract:

The present invention provides a method for the treatment of individuals diagnosed with a childhood behavioral disorder such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) by administering an effective amount of memantine.

US Patent:

20080150532, Jun 26, 2008

Filed:

Dec 21, 2006

Appl. No.:

11/614593

Inventors:

Glenn Scott Slavin - Silver Spring MD, US
Sandeep Narendra Gupta - Hanover MD, US

Assignee:

GENERAL ELECTRIC COMPANY - Schenectady NY

International Classification:

G01R 33/50
G01R 33/48

US Classification:

324318, 702 19

Abstract:

A method for rapid measurement of T relaxation comprises a gated, multi-time-point saturation-recovery experiment. Each saturation-recovery experiment may include multiple gating intervals to increase dynamic range of the T measurement. Multiple saturation-recovery experiments may also be used to improve accuracy and signal-to-noise of the T measurement.

US Patent:

20100076073, Mar 25, 2010

Filed:

Nov 20, 2009

Appl. No.:

12/592171

Inventors:

Sandeep Gupta - Plainsboro NJ, US
Gary Samoriski - Hisslborough NJ, US

Assignee:

MERZ PHARMA GmbH & CO. KGaA - Frankfurt am Main

International Classification:

A61K 31/13
A61K 31/343
A61P 25/24

US Classification:

514469, 514579

Abstract:

The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.